Our identification of molecular subclasses with specific drug actionable pathway alterations in 104/153 (68.0%) tumours may tailor the design of trials based on the molecular selection of patients, irrespective of the site of origin, where actionable signaling pathways include tyrosine-kinase receptors (TKR), RAS/RAF/MAPK/ERK, mTOR, and TGF-ß. This evidence concerns the gene TKTL1 and neoplasm.